ArticleBlood cancer journal2021

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.

Hilma J van der Horst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.